Infliximab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NICE (England), PHARMAC (New Zealand) and TLV (Sweden) recommended or restricted infliximab, while AWMSG (Wales) and CIPM (Spain) did not recommend it.
SMC (Scotland) has been harder on infliximab than on its own caseload: it refused 3 of 7 decisive submissions here (43%), against a base rate of 16% across everything it has assessed.
The file has been open for more than a decade: 21.7 years separate the first record, 12 Jul 2004 at SMC (Scotland), from the most recent, 3 Mar 2026 at PHARMAC (New Zealand).
HAS (France) changed its position: not recommended on 26 Apr 2006, recommended by 28 Jan 2026, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for infliximab, 2 submissions were never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 7 of 69 records date from 2023 or later.
The programme is broad: 25 distinct indication wordings are recorded for infliximab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
11 of these 69 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess infliximab, on 12 Jul 2004; CIPM (Spain) did not open a file until 12 Nov 2020 — an unusually long tail of 16.3 years between the earliest and latest system to look at it.
The record arrives in waves: 18 separate years each carry two or more decisions, spread across 20 years in total.
8 of the 9 agencies here assessed infliximab more than once, HAS (France) most often at 24 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for infliximab.
The full ledger for infliximab reads 35 recommended, 17 not recommended, 4 restricted and 3 superseded, with 10 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 28 Jan 2026 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2024 | Rheumatoid arthritis | The PBAC rescinded the November 2022 recommendation. | source |
| TLV (Sweden) | 23 Feb 2024 | Ny beredningsform av Remsima ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| CIPM (Spain) | 12 Nov 2020 | Indicación terapéutica: SECRETARIA DE ESTADO DE SANIDAD MINISTERIO SANIDAD MINISTERIO DE SANIDAD Primer biosimilar de in… | not financed by the SNS · art. 92 e | source |
| CONITEC (Brazil) | 31 Oct 2018 | Tratamento da psoríase | not incorporated | source |
64 further decisions for infliximab, across 8 agencies, are not shown here. They include the most recent record on file, 3 Mar 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 31 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- lenalidomide — same ATC class L04A — Immunosuppressants
Coverage: 69 decisions for infliximab from 9 agencies, 2004 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.